Vivitrol is an anti-dependence drug owned by Alkermes. The active ingredient in Vivitrol is naltrexone. The drug was first authorized for market use on 13 April 2006 and is available in suspension, extended release; intramuscular dosage forms. Vivitrol holds a total of 1 patent, none of which have expired.
The Vivitrol generic version is expected to be available after 15 October 2029, following the expiry of its last patent (US7919499) titled 'Naltrexone long acting formulations and methods of use'. This is taking into account possible Para IV filings.
Vivitrol is primarily used for the prevention of relapse to opioid dependence following opioid detoxification and treatment of alcohol dependence. Its active ingredient, naltrexone, works by blocking the effects of opioids in the body, which helps in reducing the cravings for these substances.
Vivitrol's main patent is US7919499, titled 'Naltrexone long acting formulations and methods of use', set to expire on 15 October 2029. The release of Vivitrol generic could possibly occur after this date; below is the detail of the patent: